Rheumaderm pp 517-520 | Cite as

Raynaud’s Phenomenon Caused by Giant Cell Arteritis

A Case Report
  • Carmel Mallia
  • B. Coleiro
  • M. Crockford
  • B. Ellul
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)


Giant cell arteritis, a systemic vasculitis that preferentially targets large and medium-sized arteries, can produce a wide variety of clinical features which may be classified into 2 groups:
  1. A)

    Systemic: malaise, fatigue, anorexia, weight loss, fever, sweats, arthralgias and, when associated with polymyalgia rheumatica, myalgias and stiffness of the neck, shoulders low back, hips and thighs.

  2. B)

    Arteritic: features resulting from ischaemia or necrosis of structures supplied by the involved blood vessels. Several different arteries can be involved with a corresponding wide range of clinical features. The most frequently affected arteries are the branches of the carotid artery with headache being the most common symptom (70–90%) [1] due to involvement of the temporal artery, whilst the most dreaded feature is blindness due to involvement of the ophthalmic artery (6–36%) [2]. Raynaud’s phenomenon as a result of subclavian artery involvement is rare [3]. One such case is described.



Subclavian Artery Giant Cell Arteritis Temporal Artery Serum Alkaline Phosphatase Ophthalmic Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Huston KA, Hunder GG, Lie JT et al. Temporal arteritis. A 25 year epidemiologic, clinical and pathological study. Ann Int Med 88: 162–167. 1978.PubMedGoogle Scholar
  2. 2.
    Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 38: 352–359. 1988.PubMedCrossRefGoogle Scholar
  3. 3.
    Ninet JP, Bachet P, Dumontet CM et al. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Amer J Med 88: 13–20. 1990.PubMedCrossRefGoogle Scholar
  4. 4.
    Breedveld FC. Giant cell arteritis: a continuum between temporal and Takayasu’s arteritis. Rheumatology Review. 1:241–253.1992.Google Scholar
  5. 5.
    Ciompi ML, Marotta G, Puccetti I et al. Behaviour of von Willebrand factor antigen in follow up of polymyalgia rheumatica/giant cell arteritis. Scand J Rheumatol 17: 491–495. 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Bosch X, Font J, Mirapelx E et al. Antineutrophil cytoplasmic antibodies in giant cell arteritis. J Rheumatol. 18: 787–788.Google Scholar
  7. 7.
    Navarro M, Cervera R, Font J et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus. 6: 6, 521–6.1997.PubMedCrossRefGoogle Scholar
  8. 8.
    Machleder HI. Vascular disorders of the upper extremity. 214–223. 1983.Google Scholar
  9. 9.
    Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. JACC. 12: 964–972. 1988.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Carmel Mallia
    • 1
  • B. Coleiro
    • 1
  • M. Crockford
    • 2
  • B. Ellul
    • 3
  1. 1.Department of MedicineSt. Luke’s HospitalMaltaUSA
  2. 2.Department of RadiologySt Luke’s HospitalMaltaUSA
  3. 3.Department of PathologySt Luke’s HospitalMaltaUSA

Personalised recommendations